Related Experiment Video

Updated: Nov 2, 2025

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

477

JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in

Rahma Menshawey1, Esraa Menshawey1, Ayman H K Alserr2

  • 1Research Department, Students' and Interns' Research Program (Research Accessibility Team), Cairo University Kasr al Ainy Faculty of Medicine.

Cardiovascular Endocrinology & Metabolism
|June 10, 2021
PubMed

Insights

Janus kinase (JAK)-inhibitors show promise in managing COVID-19 by inhibiting viral entry and reducing inflammation. Further research is needed to address safety concerns and explore benefits for specific patient groups.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Rheumatology experts propose Janus kinase (JAK)-inhibitors for COVID-19 management.
  • JAK-inhibitors' role in COVID-19 is multifaceted, potentially blocking viral entry and mitigating cytokine storms.

Purpose of the Study:

  • To review the rationale and current evidence for using JAK-inhibitors in COVID-19.
  • To explore potential benefits and risks associated with JAK-inhibitor therapy in COVID-19 patients.

Main Methods:

  • Literature review of existing studies and expert opinions on JAK-inhibitor use in COVID-19.
  • Analysis of the proposed mechanisms of action for JAK-inhibitors in viral infections.

Main Results:

  • JAK-inhibitors may prevent viral endocytosis and reduce excessive chemokine signaling at approved doses.
  • Concerns include potential reactivation of latent infections and feasibility in severe COVID-19.
  • JAK-inhibitors might benefit diabetic and obese patients by targeting dysregulated JAK-STAT pathways.

Conclusions:

  • JAK-inhibitors present a potential therapeutic strategy for COVID-19, with multifaceted effects.
  • Further investigation is warranted to optimize their use and address safety concerns, especially in vulnerable populations.
Keywords:
COVID-19Janus kinase-signal transducer and activator of transcription inhibitorbaricitnibdiabetesobesityruxolitinib

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

751
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
43
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
39
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
60
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.8K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
652